Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Comparison of Efficacy of Rifaximin, Probiotics and LOLA (L-Ornithine L-Aspartate) in Overt Hepatic Encephalopathy: A Randomized, Phase-IV, Lactulose Controlled Clinical Trial.

NCT07037394 is registered in ClinicalTrials.gov with Qurratul Ain Jamil as lead sponsor.

NCT NCT07037394
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07037394 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Comparison of Efficacy of Rifaximin, Probiotics and LOLA (L-Ornithine L-Aspartate) in Overt Hepatic Encephalopathy: A Randomized, Phase-IV, Lactulose Controlled Clinical Trial.
Lead sponsor
Qurratul Ain Jamil
Phase
Phase 4
Overall status
Completed
Start date
December 2, 2024
Completion date
April 30, 2025
Enrollment
252 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

overt hepatic encephalopathy